Success Metrics

Active Trials
4(67%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
1
17%
Ph early_phase_1
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Terminated(1)

Detailed Status

Recruiting3
Active, not recruiting1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 14 (66.7%)
Phase 21 (16.7%)

Trials by Status

active_not_recruiting117%
not_yet_recruiting117%
recruiting350%
withdrawn117%

Recent Activity

4 active trials
Showing 5 of 6
not_yet_recruitingphase_1

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07564596
recruitingphase_2

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT07096843
recruitingphase_1

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043
recruitingphase_1

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

NCT07043946
active_not_recruitingearly_phase_1

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

NCT07090655
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07564596Phase 1

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Not Yet Recruiting
NCT07096843Phase 2

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Recruiting
NCT07011043Phase 1

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Recruiting
NCT07043946Phase 1

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Recruiting
NCT07090655Early Phase 1

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

Active Not Recruiting
NCT06570434Phase 1

Phase 1b/2a in SLE With Budoputug

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6